跳至主要内容
临床试验/NCT02138461
NCT02138461已完成不适用

Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.

MDbackline, LLC1 个研究点 分布在 1 个国家目标入组 211 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
211
试验地点
1
主要终点
Tolerability of Medications as Measured by the COMTOL Validated Instrument

研究概览

简要总结

This study examines patient perceptions regarding the tolerability of two classes of glaucoma medication: bimatoprost and latanoprost.

详细描述

Patients enrolled in this study completed a validated survey instrument (COMTOL) examining tolerability of topically applied ophthalmic medications that they are already taking in their regular course of care for glaucoma. The purpose of the study is to determine whether side effects and symptoms of the drugs already being taken cause problems with activities of daily living.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with glaucoma taking either bimatoprost or latanoprost

排除标准

  • patients taking other medication or with other causes for ocular surface symptoms

结局指标

主要结局

Tolerability of Medications as Measured by the COMTOL Validated Instrument

时间窗: at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study

Patients who are already taking the medications of interest will be enrolled from a general ophthalmology practice. Immediately after consenting to participate, they will complete a validated survey instrument called the Comparison of Ophthalmic Medication for Primary Outcome Measure Tolerability (COMTOL) questionnaire (Ophthalmology 1997; : 104:334-342). Because this study will not be a crossover trial design, and patients will only continue taking the medications they were prescribed in the course of their glaucoma therapy, the modified version will eliminate questions in the COMTOL related to subjective comparison of two medications and instead focus on tolerability of the single medication being taken by test subjects.

次要结局

未报告次要终点

研究者

发起方
MDbackline, LLC
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验